OSLO, Norway, May 9, 2019 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage biotechnology company developing
immune activators to target hard-to-treat solid tumors, today
announces its first quarter 2019 results.
A meeting for investors, analysts and press will take place
in Oslo today at 10:00 CET (details below).
HIGHLIGHTS FOR THE FIRST QUARTER 2019
- The first patient was treated in the dose expansion cohort of
the ONCOS-102 trial in checkpoint inhibitor refractory advanced
melanoma
- Finalized the first development stage for new viruses, filed
patents on three viruses
- The Parker Institute for Cancer Immunotherapy, Cancer Research
Institute and Targovax signed a collaboration agreement to run a
clinical trial with the TG vaccine in advanced pancreatic cancer in
combination with other immunotherapies
- The European Patent Office granted a European patent which
protects Targovax's TG01/02 mutant-RAS specific peptides and mutant
RAS specific T-cells, for the treatment of cancer in combination
with chemotherapies. This extends TG01/02 IP protection to
2034
- The US Patent and Trademark Office issued a Notice of Allowance
in the US on a patent covering the TG mutant-RAS neoantigen vaccine
platform. The allowed patent protects the composition of matter of
Targovax's mutant-RAS specific neoantigen peptides and vaccines
TG02 and TG03
- Targovax granted Zelluna Immunotherapy an FTO license to
intellectual property relating to mutant RAS T-cell receptor
technology
- Targovax successfully completed a Private Placement (PP),
raising gross proceeds of NOK
74m
POST-PERIOD HIGHLIGHTS
- In May, Targovax announced the completion of enrollment of
ONCOS-102 trial in mesothelioma. Randomized data expected around
New Year
Øystein Soug, CEO commented: "Throughout the first
quarter of 2019 we have seen strong recruitment in several of our
clinical trials. The first patient in the second cohort in the
melanoma trial was dosed. The mesothelioma and peritoneal trials
recruited very well. Based on recent RAS vaccine data, we entered
into a research collaboration agreement with the Parker Institute
for Cancer Immunotherapy and CRI. Within this collaboration, the
intention is to conduct a clinical trial in combination with other
anti-cancer treatments. This collaboration may be important, not
only by testing TG vaccination in a new patient population – it
also enables us to work with some of the world's leading experts in
immunotherapy and pancreatic cancer. This may open up many new
opportunities for the TG program in the future."
Presentation
The presentation will take place at 10:00
CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed
here.
Reporting material
TRVX 1Q19 report
TRVX 1Q19 presentation
The quarterly report and presentation are also available at the
website www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--first-quarter-2019-results,c2807352
The following files are available for download:
https://mb.cision.com/Public/17093/2807352/a99bff69dc929a4b.pdf
|
TRVX 1Q19
report
|
https://mb.cision.com/Public/17093/2807352/8fb2b1a64897b7c5.pdf
|
TRVX 1Q19
presentation
|
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-first-quarter-2019-results-300846984.html
SOURCE Targovax